Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Achieve Life Sciences Inc (ACHV)
NASDAQ:ACHV
Achieve Life Sciences (ACHV) Stock Price & Analysis
1,050 Followers
ACHV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.03 - $5.98
Previous Close$4.63
Volume2.26K
Average Volume (3M)236.65K
Market Cap
$159.52M
Enterprise Value$109.80M
Total Cash (Recent Filing)$66.40M
Total Debt (Recent Filing)$17.19M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Aug 08, 2024EPS Estimate
-$0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.29
Shares Outstanding34,341,303
10 Day Avg. Volume234,122
30 Day Avg. Volume236,647
Standard Deviation0.26
R-Squared0.07
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)3.61
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-4.58
Forecast
1Y Price Target
$16.40Price Target Upside253.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Achieve Life Sciences News
PremiumCompany Announcements
Achieve Life Sciences Negotiates Refinancing with Silicon Valley Bank
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessPositive results from the ORCA-2 and ORCA-3 Phase 3 studies met primary and secondary endpoints, supporting the treatment's efficacy and highlighting its potential for market success.
Financial HealthAchieve reported a strengthened balance sheet through financing, which extends the cash runway well into the future, indicating a solid financial position for sustained operations.
Regulatory MilestonesFDA alignment secures the next steps for Achieve to submit an NDA for cytisinicline, showcasing progress in the regulatory process and potential market approval.
Bears Say
Drug Approval DelaysAnticipate a one-year delay in the approval and launch of cytisinicline due to FDA's demand for more extensive safety data.
Regulatory ChallengesFDA insists on an additional long-term exposure study for cytisinicline, questioning the validity of the current safety data.
Stock ImpactAnalyst revises the price target for the company's stock downward from $35 to $25 based on anticipated approval delays for cytisinicline.
---
Ownership Overview
12.89% Insiders
9.66% Mutual Funds
8.58% Other Institutional Investors
68.87% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ACHV FAQ
What was Achieve Life Sciences Inc’s price range in the past 12 months?
Achieve Life Sciences Inc lowest stock price was $3.03 and its highest was $5.98 in the past 12 months.
What is Achieve Life Sciences Inc’s market cap?
Currently, no data Available
When is Achieve Life Sciences Inc’s upcoming earnings report date?
Achieve Life Sciences Inc’s upcoming earnings report date is Aug 08, 2024 which is in 17 days.
How were Achieve Life Sciences Inc’s earnings last quarter?
Achieve Life Sciences Inc released its earnings results on May 09, 2024. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.242 by -$0.018.
Is Achieve Life Sciences Inc overvalued?
According to Wall Street analysts Achieve Life Sciences Inc’s price is currently Undervalued.
Does Achieve Life Sciences Inc pay dividends?
Achieve Life Sciences Inc does not currently pay dividends.
What is Achieve Life Sciences Inc’s EPS estimate?
Achieve Life Sciences Inc’s EPS estimate is -$0.24.
How many shares outstanding does Achieve Life Sciences Inc have?
Achieve Life Sciences Inc has 34,341,305 shares outstanding.
What happened to Achieve Life Sciences Inc’s price movement after its last earnings report?
Achieve Life Sciences Inc reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.242. Following the earnings report the stock price went up 1.766%.
Which hedge fund is a major shareholder of Achieve Life Sciences Inc?
Currently, no hedge funds are holding shares in ACHV
---
Achieve Life Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.40 (253.07% Upside)
$16.40 (253.07% Upside)
Blogger Sentiment
Bullish
ACHV Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.1%
Last 30 Days ▼ 7.5%
Last 30 Days ▼ 7.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-12.31%
12-Months-Change
Fundamentals
Return on Equity
-109.49%
Trailing 12-Months
Asset Growth
236.71%
Trailing 12-Months
Company Description
Achieve Life Sciences Inc
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products, cytisine, is a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
---
ACHV Earnings Call
Q1 2024
0:00 / 0:00
---
ACHV Stock 12 Month Forecast
Average Price Target
$16.40
▲(253.07% Upside)
Technical Analysis
Best Analysts Covering ACHV
1 Year
1 Year Success Rate
5/12 ratings generated profit
1 Year Average Return
+8.76%
reiterated a buy rating 2 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 41.67% of your transactions generating a profit, with an average return of +8.76% per trade.
---